Bortezomib Patent Expiration
Bortezomib is Used for treating multiple myeloma patients who have not responded to previous therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc
Bortezomib Patents
Given below is the list of patents protecting Bortezomib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bortezomib | US11679119 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US11752164 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US12005069 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US8962572 | Bortezomib formulations | Nov 03, 2032 | Fresenius Kabi Usa |
| Velcade |
US6713446 (Pediatric) | Formulation of boronic acid compounds |
Jul 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade |
US6958319 (Pediatric) | Formulation of boronic acid compounds |
Jul 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade | US6713446 | Formulation of boronic acid compounds |
Jan 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade | US6958319 | Formulation of boronic acid compounds |
Jan 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade |
US5780454 (Pediatric) | Boronic ester and acid compounds |
Nov 03, 2017
(Expired) | Takeda Pharms Usa |
| Velcade | US5780454 | Boronic ester and acid compounds |
May 03, 2017
(Expired) | Takeda Pharms Usa |
| Velcade | US6083903 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6297217 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6617317 | Boronic ester and acid compositions |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6747150 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US7119080 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list recent legal activities going on the following patents of Bortezomib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Sep, 2023 | US11752164 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752164 |
| Recordation of Patent Grant Mailed Critical | 12 Sep, 2023 | US11752164 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 12 Sep, 2023 | US11752164 |
| Email Notification Critical | 24 Aug, 2023 | US11752164 |
| Issue Notification Mailed Critical | 23 Aug, 2023 | US11752164 |
| Electronic Review Critical | 10 Aug, 2023 | US11752164 |
| Email Notification Critical | 10 Aug, 2023 | US11752164 |
Bortezomib's Family Patents
Explore Our Curated Drug Screens
Bortezomib Generic API Manufacturers
Several generic applications have been filed for Bortezomib. The first generic version for Bortezomib was by Fresenius Kabi Usa Llc and was approved on May 2, 2022. And the latest generic version is by Hetero Labs Ltd Unit Vi and was approved on May 3, 2024.
Given below is the list of companies who have filed for Bortezomib generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Discontinued | INTRAVENOUS, SUBCUTANEOUS | N/A | Jul 26, 2022 |
2. APOTEX
Apotex Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
4. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
5. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
6. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
7. HETERO LABS LTD VI
Hetero Labs Ltd Unit Vi has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Vi.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 3, 2024 |
8. HOSPIRA
Hospira Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
Manufacturing Plant Locations New
Hospira's manufacturing plants are situated in 3 countries - Australia, United States, Dominican Republic (the). Given below are the details of these plant locations as well as the firm names of Hospira as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia |
| |||||||||||||
| United States |
| |||||||||||||
| Dominican Republic (the) |
| |||||||||||||
9. JIANGSU HANSOH PHARM
Jiangsu Hansoh Pharmaceutical Group Co Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Jiangsu Hansoh Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
Manufacturing Plant Locations New
Jiangsu Hansoh Pharm's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Jiangsu Hansoh Pharm as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| China |
| |||||
10. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
11. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||
12. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Discontinued | INTRAVENOUS, SUBCUTANEOUS | N/A | Oct 31, 2022 |
13. PHARMASCIENCE INC
Pharmascience Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Pharmascience Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
Manufacturing Plant Locations New
Pharmascience Inc's manufacturing plants are situated in 1 country - Canada. Given below are the details of these plant locations as well as the firm names of Pharmascience Inc as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Canada |
| |||||
14. QILU PHARM HAINAN
Qilu Pharmaceutical Hainan Co Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |
15. RELIANCE LIFE SCI
Reliance Life Sciences Private Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Reliance Life Sci.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Oct 11, 2022 |
Manufacturing Plant Locations New
Reliance Life Sci's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Reliance Life Sci as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
16. SANDOZ
Sandoz Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | Jul 26, 2022 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
17. SCINOPHARM TAIWAN
Scinopharm Taiwan Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Scinopharm Taiwan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Discontinued | INTRAVENOUS, SUBCUTANEOUS | N/A | Sep 26, 2023 |
Manufacturing Plant Locations New
Scinopharm Taiwan's manufacturing plants are situated in 1 country - Taiwan. Given below are the details of these plant locations as well as the firm names of Scinopharm Taiwan as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Taiwan |
| |||
18. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Discontinued | INTRAVENOUS, SUBCUTANEOUS | N/A | May 2, 2022 |
19. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.5MG/VIAL | injectable | Prescription | INTRAVENOUS, SUBCUTANEOUS | AP | May 2, 2022 |